Molecular aspects of the translocation process by ABC proteins

Comprehensive Biophysics

Volumn 8, Issue , 2012, Pages 145-173

  Callaghan, R ^a   George, A M ^b   Kerr, I D ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ABC proteins; ATP hydrolysis; Bioenergetic coupling; Drug binding site; Drug translocation; Export protein; Import protein; Membrane protein structure; Membrane transport; Multidrug resistance; Nucleotide binding domain; Periplasmic binding protein; Transport mechanism; Uptake

Indexed keywords

EID: 84882787424     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374920-8.00812-2     Document Type: Chapter

References (341)

1. Davidson A.L., Dassa E., Orelle C., Chen J. Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol. Mol. Biol. Rev. 2008, 72(2):317-364.
2. Dean M., Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genom. Hum. Genet. 2005, 6(1):123-142.
3. Schneider E., Hunke S. ATP-binding-cassette (ABC) transport systems: Functional and structural aspects of the ATP-hydrolyzing subunits/domains. FEMS Microbiol. Rev. 1998, 22(1):1-20.
4. Verrier P.J., Bird D., Burla B., Dassa E., Forestier C., Geisler M., Klein M., Kolukisaoglu U., Lee Y., Martinoia E., Murphy A., Rea P.A., Samuels L., Schulz B., Spalding E.J., Yazaki K., Theodoulou F.L. Plant ABC proteins - A unified nomenclature and updated inventory. Trends Plant Sci. 2008, 13(4):151-159.
5. Chakraburtty K. Translational regulation by ABC systems. Res. Microbiol. 2001, 152(3-4):391-399.
6. Goosen N., Moolenaar G.F. Role of ATP hydrolysis by UvrA and UvrB during nucleotide excision repair. Res. Microbiol. 2001, 152(3-4):401-409.
7. Locher K.P., Lee A.T., Rees D.C. The E. coli BtuCD structure: A framework for ABC transporter architecture and mechanism. Science 2002, 296(5570):1091-1098.
8. Kadaba N.S., Kaiser J.T., Johnson E., Lee A., Rees D.C. The high-affinity E. coli methionine ABC transporter: Structure and allosteric regulation. Science 2008, 321(5886):250-253.
9. Rees D.C., Johnson E., Lewinson O. ABC transporters: The power to change. Nat. Rev. Mol. Cell Biol. 2009, 10(3):218-227.
10. Jones P.M., O'Mara M.L., George A.M. ABC transporters: A riddle wrapped in a mystery inside an enigma. Trends Biochem. Sci. 2009, 34(10):520-531.
11. Oswald C., Holland I.B., Schmitt L. The motor domains of ABC-transporters. What can structures tell us?. Naunyn-Schmiedeberg's Arch. Pharmacol. 2006, 372(6):385-399.
12. Chen J., Lu G., Lin J., Davidson A.L., Quiocho F.A. A tweezers-like motion of the ATP-binding cassette dimer in an ABC transport cycle. Mol. Cell 2003, 12(3):651-661.
13. Hopfner K.P., Karcher A., Shin D.S., Craig L., Arthur L.M., Carney J.P., Tainer J.A. Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily. Cell 2000, 101:789-800.
14. Hung L.W., Wang I.X., Nikaido K., Liu P.Q., Ames G.F., Kim S.H. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 1998, 396(6712):703-707.
15. Karpowich N., Martsinkevich O., Millen L., Yuan Y.R., Dai P.L., MacVey K., Thomas P.J., Hunt J.F. Crystal structures of the MJ1267 ATP binding cassette reveal an induced-fit effect at the ATPase active site of an ABC transporter. Structure (Cambridge) 2001, 9(7):571-586.
16. 12 suggest a functionally important reduction in protein mobility upon ligand binding. J. Biol. Chem. 2003, 278(10):8429-8434.
17. Zaitseva J., Jenewein S., Oswald C., Jumpertz T., Holland I.B., Schmitt L. A molecular understanding of the catalytic cycle of the nucleotide-binding domain of the ABC transporter HlyB. Biochem. Soc. Trans. 2005, 33(Pt 5):990-995.
18. Gaudet R., Wiley D.C. Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing. EMBO J. 2001, 20(17):4964-4972.
19. Berntsson R.P., Smits S.H., Schmitt L., Slotboom D.J., Poolman B. A structural classification of substrate-binding proteins. FEBS Lett. 2010, 584(12):2606-2617.
20. - ion channels by phosphorylation and dephosphorylation. Adv. Second Messenger Phosphoprotein Res. 1999, 33:79-106.
21. - channel by ATP-driven nucleotide-binding domain dimerisation. J. Physiol. 2009, 587(Pt 10):2151-2161.
22. Cheng S.H., Rich D.P., Marshall J., Gregory R.J., Welsh M.J., Smith A.E. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 1991, 66(5):1027-1036.
23. Dulhanty A.M., Riordan J.R. Phosphorylation by cAMP-dependent protein kinase causes a conformational change in the R domain of the cystic fibrosis transmembrane conductance regulator. Biochemistry 1994, 33(13):4072-4079.
24. - channel in CHO cells stably expressing the cystic fibrosis gene. Nature 1991, 352(6336):628-631.
25. Chang X.B., Tabcharani J.A., Hou Y.X., Jensen T.J., Kartner N., Alon N., Hanrahan J.W., Riordan J.R. Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. J. Biol. Chem. 1993, 268(15):11304-11311.
26. Mense M., Vergani P., White D.M., Altberg G., Nairn A.C., Gadsby D.C. In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer. EMBO J. 2006, 25(20):4728-4739.
27. Ostedgaard L.S., Jennings M.L., Karniski L.P., Schuster V.L. A 45-kDa protein antigenically related to band 3 is selectively expressed in kidney mitochondria. Proc. Natl. Acad. Sci. USA 1991, 88(3):981-985.
28. Albrecht C., Viturro E. The ABCA subfamily - Gene and protein structures, functions and associated hereditary diseases. Pflugers Arch. 2007, 453(5):581-589.
29. Broccardo C., Luciani M., Chimini G. The ABCA subclass of mammalian transporters. Biochim. Biophys. Acta 1999, 1461(2):395-404.
30. Favari E., Calabresi L., Adorni M.P., Jessup W., Simonelli S., Franceschini G., Bernini F. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 2009, 48(46):11067-11074.
31. Lee J.Y., Parks J.S. ATP-binding cassette transporter AI and its role in HDL formation. Curr. Opin. Lipidol. 2005, 16(1):19-25.
32. Wang N., Tall A.R. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 2003, 23(7):1178-1184.
33. Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Ozcurumez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 1999, 22(4):347-351.
34. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Genest J., Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 1999, 22(4):336-345.
35. Marcil M., Brooks-Wilson A., Clee S.M., Roomp K., Zhang L.H., Yu L., Collins J.A., van Dam M., Molhuizen H.O., Loubster O., Ouellette B.F., Sensen C.W., Fichter K., Mott S., Denis M., Boucher B., Pimstone S., Genest J., Kastelein J.J., Hayden M.R. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999, 354(9187):1341-1346.
36. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., Deleuze J.F., Brewer H.B., Duverger N., Denefle P., Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 1999, 22(4):352-355.
37. Tsui L.C. Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: A report from the Cystic Fibrosis Genetic Analysis Consortium. Hum. Mutat. 1992, 1(3):197-203.
38. Jensen T.J., Loo M.A., Pind S., Williams D.B., Goldberg A.L., Riordan J.R. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995, 83(1):129-135.
39. Kartner N., Augustinas O., Jensen T.J., Naismith A.L., Riordan J.R. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat. Genet. 1992, 1(5):321-327.
40. Riordan J.R. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Am. J. Hum. Genet. 1999, 64(6):1499-1504.
41. Boucher R.C. Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy. Annu. Rev. Med. 2007, 58:157-170.
42. Lewis M.J., Lewis E.H., Amos J.A., Tsongalis G.J. Cystic fibrosis. Am. J. Clin. Pathol. 2003, 120(Suppl):S3-S13.
43. Tiddens H.A., Donaldson S.H., Rosenfeld M., Pare P.D. Cystic fibrosis lung disease starts in the small airways: Can we treat it more effectively?. Pediatr. Pulmonol. 2010, 45(2):107-117.
44. Wilschanski M. Patterns of gastrointestinal disease associated with mutations of CFTR. Curr. Gastroenterol. Rep. 2008, 10(3):316-323.
45. Allikmets R. Further evidence for an association of ABCR alleles with age-related macular degeneration. The International ABCR Screening Consortium. Am. J. Hum. Genet. 2000, 67(2):487-491.
46. Allikmets R., Singh N., Sun H., Shroyer N.F., Hutchinson A., Chidambaram A., Gerrard B., Baird L., Stauffer D., Peiffer A., Rattner A., Smallwood P., Li Y., Anderson K.L., Lewis R.A., Nathans J., Leppert M., Dean M., Lupski J.R. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat. Genet. 1997, 15(3):236-246.
47. Margalit E., Sunness J.S., Green W.R., Kelman S.E., Schachat A.P., Fiergang D., Allikmets R. Stargardt disease in a patient with retinoblastoma. Arch. Ophthalmol. 2003, 121(11):1643-1646.
48. Martinez-Mir A., Paloma E., Allikmets R., Ayuso C., del Rio T., Dean M., Vilageliu L., Gonzalez-Duarte R., Balcells S. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. Nat. Genet. 1998, 18(1):11-12.
49. Briggs C.E., Rucinski D., Rosenfeld P.J., Hirose T., Berson E.L., Dryja T.P. Mutations in ABCR (ABCA4) in patients with Stargardt macular degeneration or cone-rod degeneration. Invest. Ophthalmol. Vis. Sci. 2001, 42(10):2229-2236.
50. Lewis R.A., Shroyer N.F., Singh N., Allikmets R., Hutchinson A., Li Y., Lupski J.R., Leppert M., Dean M. Genotype/phenotype analysis of a photoreceptor-specific ATP-binding cassette transporter gene, ABCR, in Stargardt disease. Am. J. Hum. Genet. 1999, 64(2):422-434.
51. Rivera A., White K., Stohr H., Steiner K., Hemmrich N., Grimm T., Jurklies B., Lorenz B., Scholl H.P., Apfelstedt-Sylla E., Weber B.H. A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration. Am. J. Hum. Genet. 2000, 67(4):800-813.
52. Rozet J.M., Gerber S., Souied E., Perrault I., Chatelin S., Ghazi I., Leowski C., Dufier J.L., Munnich A., Kaplan J. Spectrum of ABCR gene mutations in autosomal recessive macular dystrophies. Eur. J. Hum. Genet. 1998, 6(3):291-295.
53. Mata N.L., Weng J., Travis G.H. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc. Natl. Acad. Sci. USA 2000, 97(13):7154-7159.
54. Weng J., Mata N.L., Azarian S.M., Tzekov R.T., Birch D.G., Travis G.H. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 1999, 98(1):13-23.
55. Beharry S., Zhong M., Molday R.S. N-retinylidene-phosphatidylethanolamine is the preferred retinoid substrate for the photoreceptor-specific ABC transporter ABCA4 (ABCR). J. Biol. Chem. 2004, M405216200.
56. Sun H., Molday R.S., Nathans J. Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease. J. Biol. Chem. 1999, 274(12):8269-8281.
57. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990, 38(9):1277-1287.
58. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 86(2):695-698.
59. Flens M.J., Zaman G.J., van der Valk P., Izquierdo M.A., Schroeijers A.B., Scheffer G.L., van der Groep P., de Haas M., Meijer C.J., Scheper R.J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 1996, 148(4):1237-1247.
60. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61(8):3458-3464.
61. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., Dahlin A., Evers R., Fischer V., Hillgren K.M., Hoffmaster K.A., Ishikawa T., Keppler D., Kim R.B., Lee C.A., Niemi M., Polli J.W., Sugiyama Y., Swaan P.W., Ware J.A., Wright S.H., Yee S.W., Zamek-Gliszczynski M.J., Zhang L. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9(3):215-236.
62. McDevitt C., Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors?. Pharmacol. Ther. 2007, 113:429-441.
63. Honda Y., Ushigome F., Koyabu N., Morimoto S., Shoyama Y., Uchiumi T., Kuwano M., Ohtani H., Sawada Y. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. Pharmacol. 2004, 143(7):856-864.
64. Wacher V.J., Wu C.Y., Benet L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13(3):129-134.
65. Zhang Y., Benet L.Z. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 2001, 40(3):159-168.
66. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
67. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8(5):411-424.
68. Modok S., Mellor H.R., Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 2006, 6(4):350-354.
69. Adachi T., Nakagawa H., Chung I., Hagiya Y., Hoshijima K., Noguchi N., Kuo M.T., Ishikawa T. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J. Exp. Ther. Oncol. 2007, 6(4):335-348.
70. Callaghan R., Crowley E., Potter S., Kerr I.D. P-glycoprotein: So many ways to turn it on. J. Clin. Pharmacol. 2008, 48(3):365-378.
71. Ishikawa T., Kuo M.T., Furuta K., Suzuki M. The human multidrug resistance-associated protein (MRP) gene family: From biological function to drug molecular design. Clin. Chem. Lab. Med. 2000, 38(9):893-897.
72. Shtil A.A., Azare J. Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int. Rev. Cytol. 2005, 246:1-29.
73. Dassa E. Phylogenetic and functional classification of ABC (ATP-binding cassette) systems. ABC Proteins: From Bacteria to Man 2003, 81-106. Elsevier, London. I.B. Holland, S.P.C. Cole, K. Kuchler, C.F. Higgins (Eds.).
74. Polissi A., Georgopoulos C. Mutational analysis and properties of the msbA gene of Escherichia coli, coding for an essential ABC family transporter. Mol. Microbiol. 1996, 20(6):1221-1233.
75. Zhou Z., White K.A., Polissi A., Georgopoulos C., Raetz C.R.H. Function of Escherichia coli MsbA, an essential ABC family transporter, in lipid A and phospholipid biosynthesis. J. Biol. Chem. 1998, 273(20):12466-12475.
76. Raetz C.R., Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 2002, 71:635-700.
77. Doerrler W.T., Raetz C.R.H. ATPase activity of the MsbA lipid flippase of Escherichia coli. J. Biol. Chem. 2002, 277(39):36697-36705.
78. Doerrler W.T., Reedy M.C., Raetz C.R.H. An Escherichia coli mutant defective in lipid export. J. Biol. Chem. 2001, 276(15):11461-11464.
79. Eckford P.D.W., Sharom F.J. Functional characterization of Escherichia coli MsbA: Interaction with nucleotides and substrates. J. Biol. Chem. 2008, 283(19):12840-12850.
80. Reuter G., Janvilisri T., Venter H., Shahi S., Balakrishnan L., van Veen H.W. The ATP binding cassette multidrug transporter LmrA and lipid transporter MsbA have overlapping substrate specificities. J. Biol. Chem. 2003, 278(37):35193-35198.
81. Lubelski J., Konings W.N., Driessen A.J. Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiol. Mol. Biol. Rev. 2007, 71(3):463-476.
82. Jones P.M., George A.M. Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling. Int. J. Parasitol. 2005, 35(5):555-566.
83. Parcej D., Tampe R. ABC proteins in antigen translocation and viral inhibition. Nat. Chem. Biol. 2010, 6(8):572-580.
84. Bear C.E., Li C.H., Kartner N., Bridges R.J., Jensen T.J., Ramjeesingh M., Riordan J.R. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992, 68(4):809-818.
85. Knowles M., Gatzy J., Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J. Clin. Invest. 1983, 71(5):1410-1417.
86. Accardi A., Picollo A. CLC channels and transporters: Proteins with borderline personalities. Biochim. Biophys. Acta 2010, 1798(8):1457-1464.
87. Aittoniemi J., Fotinou C., Craig T.J., de Wet H., Proks P., Ashcroft F.M. Review. SUR1: A unique ATP-binding cassette protein that functions as an ion channel regulator. Philos. Trans. R. Soc. London B Biol. Sci. 2009, 364(1514):257-267.
88. Clement J.P.t., Kunjilwar K., Gonzalez G., Schwanstecher M., Panten U., Aguilar-Bryan L., Bryan J. Association and stoichiometry of K(ATP) channel subunits. Neuron 1997, 18(5):827-838.
89. Mikhailov M.V., Campbell J.D., de Wet H., Shimomura K., Zadek B., Collins R.F., Sansom M.S., Ford R.C., Ashcroft F.M. 3-D structural and functional characterization of the purified KATP channel complex Kir6.2-SUR1. EMBO J. 2005, 24(23):4166-4175.
90. Ashcroft F.M. ATP-sensitive potassium channelopathies: Focus on insulin secretion. J. Clin. Invest. 2005, 115(8):2047-2058.
91. Gloyn A.L., Siddiqui J., Ellard S. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat. 2006, 27(3):220-231.
92. Hattersley A.T., Ashcroft F.M. Activating mutations in Kir6.2 and neonatal diabetes: New clinical syndromes, new scientific insights, and new therapy. Diabetes 2005, 54(9):2503-2513.
93. Jardetzky O. Simple allosteric model for membrane pumps. Nature 1966, 211(5052):969-970.
94. Van Winkle L.J. Biomembrane Transport 1999, Academic Press, San Diego.
95. Tamai I., Safa A.R. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J. Biol. Chem. 1991, 266:16796-16800.
96. 3H]vinblastine binding to P-glycoprotein of MCF-7 Adr cells by dexniguldipine. Biochem. Pharmacol. 1995, 49:1851-1861.
97. Ferry D.R., Russell M.A., Cullen M.H. P-glycoprotein possesses a 1,4-dihydropyridine selective drug acceptor site which is allosterically coupled to a vinca alkaloid selective binding site. Biochem. Biophys. Res. Commun. 1992, 188:440-445.
98. Shapiro A.B., Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur. J. Biochem. 1997, 250(1):130-137.
99. Shapiro A.B., Fox K., Lam P., Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 1999, 259(3):841-850.
100. Martin C., Berridge G., Higgins C.F., Callaghan R. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br. J. Pharmacol. 1997, 122(4):765-771.
101. Martin C., Berridge G., Higgins C.F., Mistry P., Charlton P., Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 2000, 58:624-632.
102. Martin C., Berridge G., Mistry P., Higgins C., Charlton P., Callaghan R. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 1999, 128(2):403-411.
103. Dey S., Ramachandra M., Pastan I., Gottesman M.M., Ambudkar S.V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA 1997, 94(20):10594-10599.
104. Wang E.J., Casciano C.N., Clement R.P., Johnson W.W. Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta 2000, 1481(1):63-74.
105. Wang E.J., Casciano C.N., Clement R.P., Johnson W.W. Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity. Arch. Biochem. Biophys. 2000, 383(1):91-98.
106. Orlowski S., Mir L.M., Belehradek J., Garrigos M. Effects of steroids and verapamil on P-glycoprotein ATPase activity: Progesterone, desoxycorticosterone and verapamil are mutually non-exclusive modulators. Biochem. J. 1996, 317:515-522.
107. Callaghan R., Berridge G., Ferry D.R., Higgins C.F. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim. Biophys. Acta 1997, 1328(2):109-124.
108. Sharom F.J., Yu X., Chu J.W., Doige C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem. J. 1995, 308(Pt 2):381-390.
109. Urbatsch I.L., Al-Shawi M.K., Senior A.E. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 1994, 33:7069-7076.
110. Al-Shawi M.K., Polar M.K., Omote H., Figler R.A. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J. Biol. Chem. 2003, 278(52):52629-52640.
111. Krupka R.M. Uncoupled active transport mechanisms accounting for low selectivity in multidrug carriers: P-glycoprotein and SMR transporters. J. Membr. Biol. 1999, 172:129-143.
112. Garrigos M., Mir L.M., Orlowski S. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase: Further experimental evidence for a multisite model. Eur. J. Biochem. 1997, 244:664-673.
113. van Veen H.W., Callaghan R., Soceneantu L., Sardini A., Konings W.N., Higgins C.F. A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene. Nature 1998, 391(6664):291-295.
114. Clark R., Kerr I.D., Callaghan R. Multiple drug binding sites on the R482G isoform of the ABCG2 transporter. Br. J. Pharmacol. 2006, 149:506-515.
115. Takenaka K., Morgan J.A., Scheffer G.L., Adachi M., Stewart C.F., Sun D., Leggas M., Ejendal K.F., Hrycyna C.A., Schuetz J.D. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 2007, 67(14):6965-6972.
116. Giri N., Agarwal S., Shaik N., Pan G., Chen Y., Elmquist W.F. Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: Consideration of multiple binding sites in in vitro assay design. Drug Metab. Dispos. 2009, 37(3):560-570.
117. Deeley R.G., Cole S.P. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006, 580(4):1103-1111.
118. Leslie E.M., Deeley R.G., Cole S.P. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001, 167(1):3-23.
119. Loe D.W., Almquist K.C., Deeley R.G., Cole S.P. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 1996, 271(16):9675-9682.
120. Loe D.W., Deeley R.G., Cole S.P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione. Cancer Res. 1998, 58(22):5130-5136.
121. Rothnie A., Callaghan R., Deeley R.G., Cole S.P. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J. Biol. Chem. 2006, 281(20):13906-13914.
122. Haimeur A., Conseil G., Deeley R.G., Cole S.P. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol. Pharmacol. 2004, 65(6):1375-1385.
123. Maeno K., Nakajima A., Conseil G., Rothnie A., Deeley R.G., Cole S.P. Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1). Drug Metab. Dispos. 2009, 37(7):1411-1420.
124. Higgins C.F., Gottesman M.M. Is the multidrug transporter a flippase?. Trends Biochem. Sci. 1992, 17(1):18-21.
125. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 1993, 268(29):21493-21496.
126. Raviv Y., Pollard H.B., Bruggemann E.P., Pastan I., Gottesman M.M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 1990, 265(7):3975-3980.
127. Pearce H.L., Safa A.R., Bach N.J., Winter M.A., Cirtain M.C., Beck W.T. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl. Acad. Sci. USA 1989, 86:5128-5132.
128. Neyfakh A.A. The ostensible paradox of multidrug recognition. J. Mol. Microbiol. Biotechnol. 2001, 3(2):151-154.
129. Wade H. MD recognition by MDR gene regulators. Curr. Opin. Struct. Biol. 2010, 20(4):489-496.
130. Dover L.G., Corsino P.E., Daniels I.R., Cocklin S.L., Tatituri V., Besra G.S., Futterer K. Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. J. Mol. Biol. 2004, 340(5):1095-1105.
131. Schumacher M.A., Miller M.C., Grkovic S., Brown M.H., Skurray R.A., Brennan R.G. Structural mechanisms of QacR induction and multidrug recognition. Science 2001, 294(5549):2158-2163.
132. Zheleznova E.E., Markham P.N., Neyfakh A.A., Brennan R.G. Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 1999, 96:353-362.
133. Fersht A. Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding 1998, Freeman, New York, pp 324-348.
134. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur. J. Biochem. 1998, 251:252-261.
135. Seelig A., Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 2000, 12:31-40.
136. Seelig A., Blatter X.L., Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int. J. Clin. Pharmacol. Ther. 2000, 38(3):111-121.
137. Kajiji S., Talbot F., Grizzuti K., Van Dyke-Phillips V., Agresti M., Safa A.R., Gros P. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry 1993, 32(16):4185-4194.
138. Loo T.W., Clarke D.M. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 1993, 268(27):19965-19972.
139. Pawagi A.B., Wang J., Silverman M., Reithmeier R.A., Deber C.M. Transmembrane aromatic amino acid distribution in P-glycoprotein: A functional role in broad substrate specificity. J. Mol. Biol. 1994, 235(2):554-564.
140. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 2006, 3(1):3-25.
141. van der Heide T., Poolman B.ABC transporters: One, two or four extracytoplasmic substrate-binding sites?. EMBO Rep. 2002, 3(10):938-943.
142. Higgins C.F. The role of ATP in binding-protein-dependent transport systems. Res. Microbiol. 1990, 141(3):353-360.
143. Hiles I.D., Gallagher M.P., Jamieson D.J., Higgins C.F. Molecular characterization of the oligopeptide permease of Salmonella typhimurium. J. Mol. Biol. 1987, 195(1):125-142.
144. Tame R.H., Murshudov G.N., Dodson E.J., Neil T.K., Dodson G.G., Higgins C.F., Wilkinson A.J. The structural basis of sequence-independent peptide binding by the OppA protein. Science 1994, 264:1578-1581.
145. Tanabe M., Mirza O., Bertrand T., Atkins H.S., Titball R.W., Iwata S., Brown K.A., Byrne B. Structures of OppA and PstS from Yersinia pestis indicate variability of interactions with transmembrane domains. Acta Crystallogr. D Biol. Crystallogr. 2007, 63(Pt 11):1185-1193.
146. Guyer C.A., Morgan D.G., Staros J.V. Binding specificity of the periplasmic oligopeptide-binding protein from Escherichia coli. J. Bacteriol. 1986, 168(2):775-779.
147. Fleischer R., Wengner A., Scheffel F., Landmesser H., Schneider E. Identification of a gene cluster encoding an arginine ATP-binding-cassette transporter in the genome of the thermophilic Gram-positive bacterium Geobacillus stearothermophilus strain DSMZ 13240. Microbiology 2005, 151(Pt 3):835-840.
148. Nikaido K., Ames G.F. Purification and characterization of the periplasmic lysine-, arginine-, ornithine-binding protein (LAO) from Salmonella typhimurium. J. Biol. Chem. 1992, 267(29):20706-20712.
149. Vahedi-Faridi A., Eckey V., Scheffel F., Alings C., Landmesser H., Schneider E., Saenger W. Crystal structures and mutational analysis of the arginine-, lysine-, histidine-binding protein ArtJ from Geobacillus stearothermophilus: Implications for interactions of ArtJ with its cognate ATP-binding cassette transporter, Art(MP)2. J. Mol. Biol. 2008, 375(2):448-459.
150. 12 uptake. Biochemistry 2005, 44(49):16301-16309.
151. Hvorup R.N., Goetz B.A., Niederer M., Hollenstein K., Perozo E., Locher K.P. Asymmetry in the structure of the ABC transporter-binding protein complex BtuCD-BtuF. Science 2007, 317(5843):1387-1390.
152. Borths E.L., Locher K.P., Lee A.T., Rees D.C. The structure of Escherichia coli BtuF and binding to its cognate ATP binding cassette transporter. Proc. Natl. Acad. Sci. USA 2002, 99(26):16642-16647.
153. 12-dependent enzymes. Annu. Rev. Biochem. 1997, 66:269-313.
154. 12-binding domains of methionine synthase. Science 1994, 266(5191):1669-1674.
155. 12 radicals are generated: The crystal structure of methylmalonyl-coenzyme A mutase at 2 A resolution. Structure 1996, 4(3):339-350.
156. Oldham M.L., Khare D., Quiocho F.A., Davidson A.L., Chen J. Crystal structure of a catalytic intermediate of the maltose transporter. Nature 2007, 450(7169):515-521.
157. Quiocho F.A., Spurlino J.C., Rodseth L.E. Extensive features of tight oligosaccharide binding revealed in high-resolution structures of the maltodextrin transport/chemosensory receptor. Structure 1997, 5(8):997-1015.
158. Sharff A.J., Rodseth L.E., Spurlino J.C., Quiocho F.A. Crystallographic evidence of a large ligand-induced hinge-twist motion between the two domains of the maltodextrin binding protein involved in active transport and chemotaxis. Biochemistry 1992, 31(44):10657-10663.
159. Spurlino J.C., Lu G.Y., Quiocho F.A. The 2.3-A resolution structure of the maltose- or maltodextrin-binding protein, a primary receptor of bacterial active transport and chemotaxis. J. Biol. Chem. 1991, 266(8):5202-5219.
160. Khare D., Oldham M.L., Orelle C., Davidson A.L., Chen J. Alternating access in maltose transporter mediated by rigid-body rotations. Mol. Cell 2009, 33(4):528-536.
161. Grote M., Polyhach Y., Jeschke G., Steinhoff H.J., Schneider E., Bordignon E. Transmembrane signaling in the maltose ABC transporter MalFGK2-E: Periplasmic MalF-P2 loop communicates substrate availability to the ATP-bound MalK dimer. J. Biol. Chem. 2009, 284(26):17521-17526.
162. Ehrle R., Pick C., Ulrich R., Hofmann E., Ehrmann M. Characterization of
163. Steinke A., Grau S., Davidson A., Hofmann E., Ehrmann M. Characterization of transmembrane segments 3, 4, and 5 of MalF by mutational analysis. J. Bacteriol. 2001, 183(1):375-381.
164. Bruggemann E.P., Currier S.J., Gottesman M.M., Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J. Biol. Chem. 1992, 267(29):21020-21026.
165. Bruggemann E.P., Germann U.A., Gottesman M.M., Pastan I. Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine. J. Biol. Chem. 1989, 264(26):15483-15488.
166. Greenberger L.M. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J. Biol. Chem. 1993, 268(15):11417-11425.
167. Greenberger L.M., Lisanti C.J., Silva J.T., Horwitz S.B. Domain mapping of the photoaffinity drug binding sites in P-glycoprotein encoded by mouse mdr1b. J. Biol. Chem. 1991, 266:20744-20751.
168. Isenberg B., Thole H., Tummler B., Demmer A. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. Eur. J. Biochem. 2001, 268(9):2629-2634.
169. Morris D.I., Greenberger L.M., Bruggemann E.P., Cardarelli C., Gottesman M.M., Pastan I., Seamon K.B. Localization of the forskolin labeling sites to both halves of P-glycoprotein: Similarity of the sites labeled by forskolin and prazosin. Mol. Pharmacol. 1994, 46:329-337.
170. Zhang X., Collins K.I., Greenberger L.M. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J. Biol. Chem. 1995, 270(10):5441-5448.
171. Gros P., Dhir R., Croop J., Talbot F. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc. Natl. Acad. Sci. USA 1991, 88(16):7289-7293.
172. Hafkemeyer P., Dey S., Ambudkar S.V., Hrycyna C.A., Pastan I., Gottesman M.M. Contribution to substrate specificity and transport of nonconserved residues in transmembrane domain 12 of human P-glycoprotein. Biochemistry 1998, 37(46):16400-16409.
173. Loo T.W., Clarke D.M. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J. Biol. Chem. 1993, 268(5):3143-3149.
174. Loo T.W., Clarke D.M. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 1994, 33(47):14049-14057.
175. Ma J.F., Grant G., Melera P.W. Mutations in the sixth transmembrane domain of P-glycoprotein that alter the pattern of cross-resistance also alter sensitivity to cyclosporin A reversal. Mol. Pharmacol. 1997, 51(6):922-930.
176. Sharom F.J. Characterization and functional reconstitution of the multidrug transporter. J. Bioenerg. Biomembr. 1995, 27(1):15-22.
177. Rosenberg M.F., Callaghan R., Ford R.C., Higgins C.F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem. 1997, 272(16):10685-10694.
178. Rosenberg M.F., Callaghan R., Modok S., Higgins C.F., Ford R.C. 3-D structure of P-glycoprotein: The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J. Biol. Chem. 2004, M410296200.
179. Rosenberg M.F., Callaghan R., Modok S., Higgins C.F., Ford R.C. Three-dimensional structure of P-glycoprotein: The transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J. Biol. Chem. 2005, 280(4):2857-2862.
180. Rosenberg M.F., Velarde G., Ford R.C., Martin C., Berridge G., Kerr I.D., Callaghan R., Schmidlin A., Wooding C., Linton K.J., Higgins C.F. Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle. EMBO J. 2001, 20(20):5615-5625.
181. Loo T.W., Bartlett M.C., Clarke D.M. Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane. J. Biol. Chem. 2004, 279(9):7692-7697.
182. Loo T.W., Clarke D.M. Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates. J. Biol. Chem. 1996, 271(44):27482-27487.
183. Loo T.W., Clarke D.M. Mutational analysis of the predicted first transmembrane segment of each homologous half of human P-glycoprotein suggests that they are symmetrically arranged in the membrane. J. Biol. Chem. 1996, 271(26):15414-15419.
184. Loo T.W., Clarke D.M. Identification of residues within the drug binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J. Biol. Chem. 2000, 275:39272-39278.
185. Loo T.W., Clarke D.M. The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. J. Biol. Chem. 2000, 275(8):5253-5256.
186. Loo T.W., Clarke D.M. Cross-linking of human multidrug resistance P-glycoprotein by the substrate, tris-(2-maleimidoethyl)amine, is altered by ATP hydrolysis: Evidence for rotation of a transmembrane helix. J. Biol. Chem. 2001, 276(34):31800-31805.
187. Loo T.W., Clarke D.M. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J. Biol. Chem. 2001, 276(40):36877-36880.
188. Loo T.W., Clarke D.M. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J. Membr. Biol. 2005, 206(3):173-185.
189. Loo T.W., Bartlett M.C., Clarke D.M. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem. J. 2006, 399(2):351-359.
190. Loo T.W., Bartlett M.C., Clarke D.M. Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket. Biochem. J. 2006, 396(3):537-545.
191. Loo T.W., Clarke D.M. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. 2002, 277(46):44332-44338.
192. Loo T.W., Bartlett M.C., Clarke D.M. The drug-binding pocket of the human multidrug resistance P-glycoprotein is accessible to the aqueous medium. Biochemistry 2004, 43(38):12081-12089.
193. Loo T.W., Clarke D.M. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through 'gates'?. Biochem. Biophys. Res. Commun. 2005, 329(2):419-422.
194. Chiba P., Ecker G., Schmid D., Drach J., Tell B., Goldenberg S., Gekeler V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein mediated multidrug resistance. Mol. Pharmacol. 1996, 49:1122-1130.
195. Ecker G.F., Csaszar E., Kopp S., Plagens B., Holzer W., Ernst W., Chiba P. Identification of ligand-binding regions of P-glycoprotein by activated-pharmacophore photoaffinity labeling and matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry. Mol. Pharmacol. 2002, 61(3):637-648.
196. Pleban K., Kopp S., Csaszar E., Peer M., Hrebicek T., Rizzi A., Ecker G.F., Chiba P. P-glycoprotein substrate binding domains are located at the transmembrane domain/transmembrane domain interfaces: A combined photoaffinity labeling-protein homology modeling approach. Mol. Pharmacol. 2005, 67(2):365-374.
197. Chiba P., Mihalek I., Ecker G.F., Kopp S., Lichtarge O. Role of transmembrane domain/transmembrane domain interfaces of P-glycoprotein (ABCB1) in solute transport: Convergent information from photoaffinity labeling, site directed mutagenesis and in silico importance prediction. Curr. Med. Chem. 2006, 13(7):793-805.
198. Crowley E., Callaghan R. Multidrug efflux pumps: Drug binding - Gates or cavity?. FEBS J. 2010, 277(3):530-539.
199. Martin C., Higgins C.F., Callaghan R. The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein. Biochemistry 2001, 40(51):15733-15742.
200. Becker J.P., Depret G., Van Bambeke F., Tulkens P.M., Prevost M. Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct. Biol. 2009, 9:3.
201. O'Mara M.L., Tieleman D.P. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett. 2007, 581(22):4217-4222.
202. Pajeva I.K., Globisch C., Wiese M. Comparison of the inward- and outward-open homology models and ligand binding of human P-glycoprotein. FEBS J. 2009, 276(23):7016-7026.
203. Seigneuret M., Garnier-Suillerot A. A structural model for the open conformation of the mdr1 P-glycoprotein based on the MsbA crystal structure. J. Biol. Chem. 2003, 278(32):30115-30124.
204. Stenham D.R., Campbell J.D., Sansom M.S., Higgins C.F., Kerr I.D., Linton K.J. An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulfide cross-linking and homology modeling. FASEB J. 2003, 17(15):2287-2289.
205. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., Harrell P.M., Trinh Y.T., Zhang Q., Urbatsch I.L., Chang G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323(5922):1718-1722.
206. Gottesman M.M., Ambudkar S.V., Xia D. Structure of a multidrug transporter. Nat. Biotechnol. 2009, 27(6):546-547.
207. Hollenstein K., Frei D.C., Locher K.P. Structure of an ABC transporter in complex with its binding protein. Nature 2007, 446(7132):213-216.
208. Ward A., Reyes C.L., Yu J., Roth C.B., Chang G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc. Natl. Acad. Sci. USA 2007, 104(48):19005-19010.
209. Zou P., Bortolus M., McHaourab H.S. Conformational cycle of the ABC transporter MsbA in liposomes: Detailed analysis using double electron-electron resonance spectroscopy. J. Mol. Biol. 2009, 393(3):586-597.
210. Zou P., McHaourab H.S. Alternating access of the putative substrate-binding chamber in the ABC transporter MsbA. J. Mol. Biol. 2009, 393(3):574-585.
211. Rothnie A., Storm J., Campbell J., Linton K.J., Kerr I.D., Callaghan R. The topography of transmembrane segment six is altered during the catalytic cycle of P-glycoprotein. J. Biol. Chem. 2004, 279(33):34913-34921.
212. Rothnie A., Storm J., McMahon R., Taylor A.M., Kerr I.D., Callaghan R. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. FEBS Lett. 2005, 579:3984-3990.
213. Storm J., Modok S., O'Mara M.L., Tieleman D.P., Kerr I.D., Callaghan R. Cytosolic region of TM6 in P-glycoprotein: Topographical analysis and functional perturbation by site directed labeling. Biochemistry 2008, 47(12):3615-3624.
214. Storm J., O'Mara M.L., Crowley E.H., Peall J., Tieleman D.P., Kerr I.D., Callaghan R. Residue G346 in transmembrane segment six is involved in inter-domain communication in P-glycoprotein. Biochemistry 2007, 46(35):9899-9910.
215. Crowley E., O'Mara M.L., Reynolds C., Tieleman D.P., Storm J., Kerr I.D., Callaghan R. Transmembrane helix 12 modulates progression of the ATP catalytic cycle in ABCB1. Biochemistry 2009, 48(26):6249-6258.
216. Crowley E., O'Mara M.L., Kerr I.D., Callaghan R. Transmembrane helix 12 plays a pivotal role in coupling energy provision and drug binding in ABCB1. FEBS J. 2010, 277(19):3974-3985.
217. Loo T.W., Bartlett M.C., Clarke D.M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein: Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 2003, 278(16):13603-13606.
218. Loo T.W., Bartlett M.C., Clarke D.M. Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains. J. Biol. Chem. 2003, 278(3):1575-1578.
219. Loo T.W., Bartlett M.C., Clarke D.M. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. Biochemistry 2005, 44(30):10250-10258.
220. Dawson R.J.P., Locher K.P. Structure of a bacterial multidrug ABC transporter. Nature 2006, 443(7108):180-185.
221. Hyde S.C., Emsley P., Hartshorn M.J., Mimmack M.M., Gileadi U., Pearce S.R., Gallagher M.P., Gill D.R., Hubbard R.E., Higgins C.F. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990, 346:362-365.
222. Jones P.M., George A.M. The ABC transporter structure and mechanism: Perspectives on recent research. Cell. Mol. Life Sci. 2004, 61:1-18.
223. Walker J.E., Saraste M., Runswick M.J., Gay N.J. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1982, 1(8):945-951.
224. Vetter I.R., Wittinghofer A. Nucleoside triphosphate-binding proteins: Different scaffolds to achieve phosphoryl transfer. Q. Rev. Biophys. 1999, 32(1):1-56.
225. Jones P.M., George A.M. Subunit interactions in ABC transporters: Towards a functional architecture. FEMS Microbiol. Lett. 1999, 179(2):187-202.
226. Lamers M.H., Perrakis A., Enzlin J.H., Winterwerp H.H., de Wind N., Sixma T.K. The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch. Nature 2000, 407(6805):711-717.
227. Newstead S., Fowler P.W., Bilton P., Carpenter E.P., Sadler P.J., Campopiano D.J., Sansom M.S., Iwata S. Insights into how nucleotide-binding domains power ABC transport. Structure 2009, 17(9):1213-1222.
228. Obmolova G., Ban C., Hsieh P., Yang W. Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. Nature 2000, 407(6805):703-710.
229. Pakotiprapha D., Inuzuka Y., Bowman B.R., Moolenaar G.F., Goosen N., Jeruzalmi D., Verdine G.L. Crystal structure of Bacillus stearothermophilus UvrA provides insight into ATP-modulated dimerization, UvrB interaction, and DNA binding. Mol. Cell 2008, 29(1):122-133.
230. Smith P.C., Karpowich N., Millen L., Moody J.E., Rosen J., Thomas P.J., Hunt J.F. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol. Cell 2002, 10(1):139-149.
231. Gerber S., Comellas-Bigler M., Goetz B.A., Locher K.P. Structural basis of trans-inhibition in a molybdate/tungstate ABC transporter. Science 2008, 321(5886):246-250.
232. Pinkett H.W., Lee A.T., Lum P., Locher K.P., Rees D.C. An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science 2007, 315(5810):373-377.
233. Chen J., Sharma S., Quiocho F.A., Davidson A.L. Trapping the transition state of an ATP-binding cassette transporter: Evidence for a concerted mechanism of maltose transport. Proc. Natl. Acad. Sci. USA 2001, 98(4):1525-1530.
234. Janas E., Hofacker M., Chen M., Gompf S., van der Does C., Tampe R. The ATP hydrolysis cycle of the nucleotide-binding domain of the mitochondrial ATP-binding cassette transporter Mdl1p. J. Biol. Chem. 2003, 278(29):26862-26869.
235. Loo T.W., Bartlett M.C., Clarke D.M. The 'LSGGQ' motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence. J. Biol. Chem. 2002, 277(44):41303-41306.
236. Moody J.E., Millen L., Binns D., Hunt J.F., Thomas P.J. Cooperative, ATP-dependent association of the nucleotide binding cassettes during the catalytic cycle of ATP-binding cassette transporters. J. Biol. Chem. 2002, 277(24):21111-21114.
237. Zaitseva J., Oswald C., Jumpertz T., Jenewein S., Wiedenmann A., Holland I.B., Schmitt L. A structural analysis of asymmetry required for catalytic activity of an ABC-ATPase domain dimer. EMBO J. 2006, 25(14):3432-3443.
238. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 2009, 109(7):2989-3011.
239. Kerr I.D., Jones P.M., George A.M. Multidrug efflux pumps: The structures of prokaryotic ATP-binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P-glycoproteins and homologues. FEBS J. 2010, 277(3):550-563.
240. Kos V., Ford R.C. The ATP-binding cassette family: A structural perspective. Cell. Mol. Life Sci. 2009, 66(19):3111-3126.
241. Procko E., O'Mara M.L., Bennett W.F., Tieleman D.P., Gaudet R. The mechanism of ABC transporters: General lessons from structural and functional studies of an antigenic peptide transporter. FASEB J. 2009, 23(5):1287-1302.
242. Schmitt L., Tampe R. Structure and mechanism of ABC transporters. Curr. Opin. Struct. Biol. 2002, 12(6):754-760.
243. Campbell J.D., Deol S.S., Ashcroft F.M., Kerr I.D., Sansom M.S. Nucleotide-dependent conformational changes in HisP: Molecular dynamics simulations of an ABC transporter nucleotide-binding domain. Biophys. J. 2004, 87(6):3703-3715.
244. Campbell J.D., Sansom M.S. Nucleotide binding to the homodimeric MJ0796 protein: A computational study of a prokaryotic ABC transporter NBD dimer. FEBS Lett. 2005, 579(19):4193-4199.
245. Jones P.M., George A.M. Mechanism of ABC transporters: A molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc. Natl. Acad. Sci. USA 2002, 99(20):12639-12644.
246. Jones P.M., George A.M. Nucleotide-dependent allostery within the ABC transporter ATP-binding cassette: A computational study of the MJ0796 dimer. J. Biol. Chem. 2007, 282(31):22793-22803.
247. Jones P.M., George A.M. Opening of the ADP-bound active site in the ABC transporter ATPase dimer: Evidence for a constant contact, alternating sites model for the catalytic cycle. Proteins 2009, 75(2):387-396.
248. 12 ATP-binding cassette (ABC) transporter BtuCD. J. Biol. Chem. 2004, 279(43):45013-45019.
249. Aittoniemi J., de Wet H., Ashcroft F.M., Sansom M.S. Asymmetric switching in a homodimeric ABC transporter: A simulation study. PLoS Comput. Biol. 2010, 6(4):e1000762.
250. Campbell J.D., Biggin P.C., Baaden M., Sansom M.S. Extending the structure of an ABC transporter to atomic resolution: Modeling and simulation studies of MsbA. Biochemistry 2003, 42(13):3666-3673.
251. Sonne J., Kandt C., Peters G.H., Hansen F.Y., Jensen M.O., Tieleman D.P. Simulation of the coupling between nucleotide binding and transmembrane domains in the ATP binding cassette transporter BtuCD. Biophys. J. 2007, 92(8):2727-2734.
252. Weng J.W., Fan K.N., Wang W.N. The conformational transition pathway of ATP binding cassette transporter MsbA revealed by atomistic simulations. J. Biol. Chem. 2010, 285(5):3053-3063.
253. Smith C.A., Rayment I. X-ray structure of the magnesium(II)-ADP-vanadate complex of the Dictyostelium discoideum myosin motor domain to 1.9 A resolution. Biochemistry 1996, 35(17):5404-5417.
254. Ye J., Osborne A.R., Groll M., Rapoport T.A. RecA-like motor ATPases - Lessons from structures. Biochim. Biophys. Acta 2004, 1659(1):1-18.
255. Zaitseva J., Jenewein S., Jumpertz T., Holland I.B., Schmitt L. H662 is the linchpin of ATP hydrolysis in the nucleotide-binding domain of the ABC transporter HlyB. EMBO J. 2005, 24(11):1901-1910.
256. Dittrich M., Schulten K. Zooming in on ATP hydrolysis in F1. J. Bioenerg. Biomembr. 2005, 37(6):441-444.
257. Nishizaka T., Oiwa K., Noji H., Kimura S., Muneyuki E., Yoshida M., Kinosita K. Chemomechanical coupling in F1-ATPase revealed by simultaneous observation of nucleotide kinetics and rotation. Nat. Struct. Mol. Biol. 2004, 11(2):142-148.
258. Oster G., Wang H. Reverse engineering a protein: The mechanochemistry of ATP synthase. Biochim. Biophys. Acta 2000, 1458(2-3):482-510.
259. Shimabukuro K., Yasuda R., Muneyuki E., Hara K.Y., Kinosita K., Yoshida M. Catalysis and rotation of F1 motor: Cleavage of ATP at the catalytic site occurs in 1 ms before 40 degree substep rotation. Proc. Natl. Acad. Sci. USA 2003, 100(25):14731-14736.
260. Wittinghofer A. Phosphoryl transfer in Ras proteins, conclusive or elusive?. Trends Biochem. Sci. 2006, 31(1):20-23.
261. Daumke O., Weyand M., Chakrabarti P.P., Vetter I.R., Wittinghofer A. The GTPase-activating protein Rap1GAP uses a catalytic asparagine. Nature 2004, 429(6988):197-201.
262. Pan X., Eathiraj S., Munson M., Lambright D.G. TBC-domain GAPs for Rab GTPases accelerate GTP hydrolysis by a dual-finger mechanism. Nature 2006, 442(7100):303-306.
263. Parke C.L., Wojcik E.J., Kim S., Worthylake D.K. ATP hydrolysis in Eg5 kinesin involves a catalytic two-water mechanism. J. Biol. Chem. 2010, 285(8):5859-5867.
264. Hur S., Bruice T.C. The near attack conformation approach to the study of the chorismate to prephenate reaction. Proc. Natl. Acad. Sci. USA 2003, 100(21):12015-12020.
265. Sauna Z.E., Muller M., Peng X.H., Ambudkar S.V. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). Biochemistry 2002, 41(47):13989-14000.
266. Tombline G., Bartholomew L.A., Urbatsch I.L., Senior A.E. Combined mutation of catalytic glutamate residues in the two nucleotide binding domains of P-glycoprotein generates a conformation that binds ATP and ADP tightly. J. Biol. Chem. 2004, 279(30):31212-31220.
267. Urbatsch I.L., Gimi K., Wilke-Mounts S., Senior A.E. Investigation of the role of glutamine-471 and glutamine-1114 in the two catalytic sites of P-glycoprotein. Biochemistry 2000, 39(39):11921-11927.
268. Davidson A.L., Sharma S. Mutation of a single MalK subunit severely impairs maltose transport activity in Escherichia coli. J. Bacteriol. 1997, 179(17):5458-5464.
269. Nikaido K., Ames G.F. One intact ATP-binding subunit is sufficient to support ATP hydrolysis and translocation in an ABC transporter, the histidine permease. J. Biol. Chem. 1999, 274(38):26727-26735.
270. Ostuni A., Miglionico R., Castiglione Morelli M.A., Bisaccia F. Study of the nucleotide-binding domain 1 of the human transporter protein Mrp6. Protein Pept. Lett. 2010, 17:1553-1558.
271. Suck D., Oefner C. Structure of DNase I at 2.0 A resolution suggests a mechanism for binding to and cutting DNA. Nature 1986, 321(6070):620-625.
272. 2 in a complex with a transition-state analogue. Science 1990, 250(4987):1563-1566.
273. Timm D.E., Mueller H.A., Bhanumoorthy P., Harp J.M., Bunick G.J. Crystal structure and mechanism of a carbon-carbon bond hydrolase. Structure 1999, 7(9):1023-1033.
274. Schweins T., Geyer M., Scheffzek K., Warshel A., Kalbitzer H.R., Wittinghofer A. Substrate-assisted catalysis as a mechanism for GTP hydrolysis of p21ras and other GTP-binding proteins. Nat. Struct. Biol. 1995, 2(1):36-44.
275. Verdon G., Albers S.V., Dijkstra B.W., Driessen A.J., Thunnissen A.M. Crystal structures of the ATPase subunit of the glucose ABC transporter from Sulfolobus solfataricus: Nucleotide-free and nucleotide-bound conformations. J. Mol. Biol. 2003, 330(2):343-358.
276. Yuan Y.R., Blecker S., Martsinkevich O., Millen L., Thomas P.J., Hunt J.F. The crystal structure of the MJ0796 ATP-binding cassette: Implications for the structural consequences of ATP hydrolysis in the active site of an ABC transporter. J. Biol. Chem. 2001, 276(34):32313-32321.
277. Oancea G., O'Mara M.L., Bennett W.F., Tieleman D.P., Abele R., Tampe R. Structural arrangement of the transmission interface in the antigen ABC transport complex TAP. Proc. Natl. Acad. Sci. USA 2009, 106(14):5551-5556.
278. Senior A.E., Al-Shawi M.K., Urbatsch I.L. The catalytic cycle of P-glycoprotein. FEBS Lett. 1995, 377:285-289.
279. Sharma S., Davidson A.L. Vanadate-induced trapping of nucleotides by purified maltose transport complex requires ATP hydrolysis. J. Bacteriol. 2000, 182(23):6570-6576.
280. Dawson R.J., Hollenstein K., Locher K.P. Uptake or extrusion: Crystal structures of full ABC transporters suggest a common mechanism. Mol. Microbiol. 2007, 65(2):250-257.
281. van der Does C., Tampe R. How do ABC transporters drive transport?. Biol. Chem. 2004, 385(10):927-933.
282. Higgins C.F., Linton K.J. The ATP switch model for ABC transporters. Nat. Struct. Mol. Biol. 2004, 11(10):918-926.
283. Vergani P., Lockless S.W., Nairn A.C., Gadsby D.C. CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 2005, 433(7028):876-880.
284. Sauna Z.E., Kim I.W., Nandigama K., Kopp S., Chiba P., Ambudkar S.V. Catalytic cycle of ATP hydrolysis by P-glycoprotein: Evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. Biochemistry 2007, 46(48):13787-13799.
285. Buchaklian A.H., Klug C.S. Characterization of the Walker A motif of MsbA using site-directed spin labeling electron paramagnetic resonance spectroscopy. Biochemistry 2005, 44(14):5503-5509.
286. Buchaklian A.H., Klug C.S. Characterization of the LSGGQ and H motifs from the Escherichia coli lipid A transporter MsbA. Biochemistry 2006, 45(41):12539-12546.
287. Grote M., Bordignon E., Polyhach Y., Jeschke G., Steinhoff H.J., Schneider E. A comparative electron paramagnetic resonance study of the nucleotide-binding domains' catalytic cycle in the assembled maltose ATP-binding cassette importer. Biophys. J. 2008, 95(6):2924-2938.
288. Qu Q., Russell P.L., Sharom F.J. Stoichiometry and affinity of nucleotide binding to P-glycoprotein during the catalytic cycle. Biochemistry 2003, 42(4):1170-1177.
289. Siarheyeva A., Liu R., Sharom F.J. Characterization of an asymmetric occluded state of P-glycoprotein with two bound nucleotides: Implications for catalysis. J. Biol. Chem. 2010, 285(10):7575-7586.
290. Westfahl K.M., Merten J.A., Buchaklian A.H., Klug C.S. Functionally important ATP binding and hydrolysis sites in Escherichia coli MsbA. Biochemistry 2008, 47(52):13878-13886.
291. Zolnerciks J.K., Wooding C., Linton K.J. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J. 2007, 21(14):3937-3948.
292. Dassa E., Hofnung M. Sequence of gene malG in E. coli K12: homologies between integral membrane components from binding protein-dependent transport systems. EMBO J. 1985, 4(9):2287-2293.
293. Kerppola R.E., Ames G.F. Topology of the hydrophobic membrane-bound components of the histidine periplasmic permease: Comparison with other members of the family. J. Biol. Chem. 1992, 267(4):2329-2336.
294. Mourez M., Hofnung M., Dassa E. Subunit interactions in ABC transporters: A conserved sequence of periplasmic permeases defines an important site of interaction with the ATPase subunits. EMBO J. 1997, 16:3066-3077.
295. Hunke S., Mourez M., Jehanno M., Dassa E., Schneider E. ATP modulates subunit-subunit interactions in an ATP-binding cassette transporter (MalFGK2) determined by site-directed chemical cross-linking. J. Biol. Chem. 2000, 275(20):15526-15534.
296. Choi K., Chen C.-J., Kriegler M., Roninson I.B. An altered pattern of cross-resistance in multidrug resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988, 53:519-529.
297. Loo T.W., Clarke D.M. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug stimulated ATPase activities. J. Biol. Chem. 1995, 270:21449-21452.
298. Rao U.S. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J. Biol. Chem. 1995, 270:6686-6690.
299. Currier S.J., Kane S.E., Willingham M.C., Cardarelli C.O., Pastan I., Gottesman M.M. Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J. Biol. Chem. 1992, 267(35):25153-25159.
300. Cotten J.F., Ostedgaard L.S., Carson M.R., Welsh M.J. Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 1996, 271(35):21279-21284.
301. Dawson R.J., Locher K.P. Structure of a bacterial multidrug ABC transporter. Nature 2006, 443:180-185.
302. Omote H., Figler R.A., Polar M.K., Al-Shawi M.K. Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation. Biochemistry 2004, 43(13):3917-3928.
303. Rothnie A., Storm J., McMahon R., Taylor A., Kerr I.D., Callaghan R. The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment. FEBS Lett. 2005, 579(18):3984-3990.
304. Letourneau I.J., Nakajima A., Deeley R.G., Cole S.P. Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. Biochem. Pharmacol. 2008, 75(8):1659-1669.
305. Dalmas O., Orelle C., Foucher A.E., Geourjon C., Crouzy S., Di Pietro A., Jault J.M. The Q-loop disengages from the first intracellular loop during the catalytic cycle of the multidrug ABC transporter BmrA. J. Biol. Chem. 2005, 280(44):36857-36864.
306. Sauna Z.E., Bohn S.S., Rutledge R., Dougherty M.P., Cronin S., May L., Xia D., Ambudkar S.V., Golin J. Mutations define cross-talk between the N-terminal nucleotide-binding domain and transmembrane helix-2 of the yeast multidrug transporter Pdr5: Possible conservation of a signaling interface for coupling ATP hydrolysis to drug transport. J. Biol. Chem. 2008, 283(50):35010-35022.
307. Bordignon E., Grote M., Schneider E. The maltose ATP-binding cassette transporter in the 21st century - Towards a structural dynamic perspective on its mode of action. Mol. Microbiol. 2010, 77(6):1354-1366.
308. Davidson A.L., Shuman H.A., Nikaido H. Mechanism of maltose transport in Escherichia coli: Transmembrane signaling by periplasmic binding proteins. Proc. Natl. Acad. Sci. USA 1992, 89:2360-2364.
309. Liu C.E., Liu P.Q., Wolf A., Lin E., Ames G.F. Both lobes of the soluble receptor of the periplasmic histidine permease, an ABC transporter (traffic ATPase), interact with the membrane-bound complex: Effect of different ligands and consequences for the mechanism of action. J. Biol. Chem. 1999, 274(2):739-747.
310. Landmesser H., Stein A., Bluschke B., Brinkmann M., Hunke S., Schneider E. Large-scale purification, dissociation and functional reassembly of the maltose ATP-binding cassette transporter (MalFGK(2)) of Salmonella typhimurium. Biochim. Biophys. Acta 2002, 1565(1):64.
311. Gould A.D., Telmer P.G., Shilton B.H. Stimulation of the maltose transporter ATPase by unliganded maltose binding protein. Biochemistry 2009, 48(33):8051-8061.
312. Daus M.L., Landmesser H., Schlosser A., Muller P., Herrmann A., Schneider E. ATP induces conformational changes of periplasmic loop regions of the maltose ATP-binding cassette transporter. J. Biol. Chem. 2006, 281(7):3856-3865.
313. Daus M.L., Grote M., Schneider E. The MalF P2 loop of the ATP-binding cassette transporter MalFGK2 from Escherichia coli and Salmonella enterica serovar typhimurium interacts with maltose binding protein (MalE) throughout the catalytic cycle. J. Bacteriol. 2009, 191(3):754-761.
314. Goetz B.A., Perozo E., Locher K.P. Distinct gate conformations of the ABC transporter BtuCD revealed by electron spin resonance spectroscopy and chemical cross-linking. FEBS Lett. 2009, 583(2):266-270.
315. Ward R., Keeble D.J., El-Mkami H., Norman D.G. Distance determination in heterogeneous DNA model systems by pulsed EPR. ChemBioChem 2007, 8(16):1957-1964.
316. Zou P., McHaourab H.S. Increased sensitivity and extended range of distance measurements in spin-labeled membrane proteins: Q-band double electron-electron resonance and nanoscale bilayers. Biophys. J. 2010, 98(6):L18-L20.
317. Wang G., Pincheira R., Zhang M., Zhang J.-T. Conformational changes of P-glycoprotein by nucleotide binding. Biochem. J. 1997, 328:897-904.
318. Wang G., Pincheira R., Zhang J.T. Dissection of drug-binding-induced conformational changes in P-glycoprotein. Eur. J. Biochem. 1998, 255(2):383-390.
319. Ramachandra M., Ambudkar S.V., Chen D., Hrycyna C.A., Dey S., Gottesman M.M., Pastan I. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 1998, 37(14):5010-5019.
320. Martin C., Berridge G., Mistry P., Higgins C.F., Charlton P., Callaghan R. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 2000, 39:11901-11906.
321. Payen L., Gao M., Westlake C., Theis A., Cole S.P., Deeley R.G. Functional interactions between nucleotide binding domains and leukotriene C4 binding sites of multidrug resistance protein 1 (ABCC1). Mol. Pharmacol. 2005, 67(6):1944-1953.
322. McDevitt C.A., Crowley E., Hobbs G., Starr K.J., Kerr I.D., Callaghan R., Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?. FEBS J. 2008, 275(17):4354-4362.
323. Sonveaux N., Vigano C., Shapiro A.B., Ling V., Ruysschaert J.M. Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein: A tryptophan fluorescence quenching analysis. J. Biol. Chem. 1999, 274(25):17649-17654.
324. Manciu L., Chang X., Riordan J.R., Buyse F., Ruysschaert J.M. Nucleotide-induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells. FEBS Lett. 2001, 493(1):31-35.
325. Liu R., Siemiarczuk A., Sharom F.J. Intrinsic fluorescence of the P-glycoprotein multidrug transporter: Sensitivity of tryptophan residues to binding of drugs and nucleotides. Biochemistry 2000, 39(48):14927-14938.
326. Russell P.L., Sharom F.J. Conformational and functional characterization of trapped complexes of the P-glycoprotein multidrug transporter. Biochem. J. 2006, 399(2):315-323.
327. Rosenberg M.F., Bikadi Z., Chan J., Liu X., Ni Z., Cai X., Ford R.C., Mao Q. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 2010, 18(4):482-493.
328. Orelle C., Gubellini F., Durand A., Marco S., Levy D., Gros P., Di Pietro A., Jault J.M. Conformational change induced by ATP binding in the multidrug ATP-binding cassette transporter BmrA. Biochemistry 2008, 47(8):2404-2412.
329. Maki N., Hafkemeyer P., Dey S. Allosteric modulation of human P-glycoprotein: Inhibition of transport by preventing substrate translocation and dissociation. J. Biol. Chem. 2003, 278(20):18132-18139.
330. Druley T.E., Stein W.D., Roninson I.B. Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity. Biochemistry 2001, 40(14):4312-4322.
331. Ruth A., Stein W.D., Rose E., Roninson I.B. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein. Biochemistry 2001, 40(14):4332-4339.
332. Vigano C., Margolles A., van Veen H.W., Konings W.N., Ruysschaert J.-M. Secondary and tertiary structural changes of reconstituted LmrA induced by nucleotide binding or hydrolysis. J. Biol. Chem. 2000, 275:10962-10967.
333. Csanady L., Nairn A.C., Gadsby D.C. Thermodynamics of CFTR channel gating: A spreading conformational change initiates an irreversible gating cycle. J. Gen. Physiol. 2006, 128(5):523-533.
334. Borbat P.P., Surendhran K., Bortolus M., Zou P., Freed J.H., McHaourab H.S. Conformational motion of the ABC transporter MsbA induced by ATP hydrolysis. PLoS Biol. 2007, 5(10):e271.
335. Dong J., Yang G., McHaourab H.S. Structural basis of energy transduction in the transport cycle of MsbA. Science 2005, 308(5724):1023-1028.
336. 12 ATP-binding cassette transporter BtuCD. Biophys. J. 2008, 94(2):612-621.
337. 12 ABC transporter BtuCD. Proteins 2010, 78(3):738-753.
338. Beck E.J., Yang Y., Yaemsiri S., Raghuram V. Conformational changes in a pore-lining helix coupled to cystic fibrosis transmembrane conductance regulator channel gating. J. Biol. Chem. 2008, 283(8):4957-4966.
339. Rao D.K., Kaur P. The Q-loop of DrrA is involved in producing the closed conformation of the nucleotide binding domains and in transduction of conformational changes between DrrA and DrrB. Biochemistry 2008, 47(9):3038-3050.
340. Jacso T., Grote M., Daus M.L., Schmieder P., Keller S., Schneider E., Reif B. Periplasmic loop P2 of the MalF subunit of the maltose ATP binding cassette transporter is sufficient to bind the maltose binding protein MalE. Biochemistry 2009, 48(10):2216-2225.
341. Dawson R.J., Locher K.P. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett. 2007, 581(5):935-938.